Compliance to genomic test recommendations to guide adjuvant chemotherapy decision‐making in the case of hormone receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer, in real‐life settings

Abstract Background Genomic tests are a useful tool for adjuvant chemotherapy decision‐making in the case of hormone receptor‐positive (HR+), and human epidermal growth factor receptor 2‐negative (HER2−) breast cancer with intermediate prognostic factors. Real‐life data on the use of tests can help...

ver descrição completa

Detalhes bibliográficos

Principais autores:	D. Hequet, N. Hajjaji, E. Charafe‐Jauffret, A. Boucrauta, F. Dalenc, V. Nicolai, J. Lopez, O. Tredan, E. Deluche, V. Fermeaux, L. Tixier, A. Cayre, E. Menet, F. Lerebours, R. Rouzier
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-08-01
coleção:	Cancer Medicine
Assuntos:	breast cancer deescalation genomic tests guidelines
Acesso em linha:	https://doi.org/10.1002/cam4.6315
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!